RE:RE:RE:RE:mRNA vaccine company Phase 2 trial fails on wrong biomarkerAACR 24 - BioNTech’s cancer vaccine in a phase 1 trial, patients with a difficult-to-treat type of pancreatic cancer continue to have T-cell responses. The long-term follow-up data from the early-stage trial show that eight out of 16 patients continue to enjoy an immune response up to three years after administration, as measured by activated T cells. Persistence of these T cells was associated with a longer median recurrence-free survival in those who received the vaccine, BioNTech said. The results were showcased at the American Association for Cancer Research annual meeting on April 7.
https://www.fiercebiotech.com/biotech/aacr-24-biontechs-genentech-partnered-cancer-vax-still-providing-immune-response-3-years